NCT03946449View on ClinicalTrials.gov

Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

April 28, 2022

Study Completion Date

December 14, 2023

Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
DRUG

ARO-AAT

solution for subcutaneous injection

Trial Locations (4)

1090

Research Center 1, Vienna

52074

Research Center 1, Aachen

CB2 0QQ

Research Center 3, Cambridge

EH19 3BJ

Research Center 2, Edinburgh

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY